Cas No.: | 1093403-33-8 |
Chemical Name: | 4-methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide |
Synonyms: | SRT-2104,SRT 2104 |
SMILES: | CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6 |
Formula: | C26H24N6O2S2 |
M.Wt: | 516.64 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SRT 2104 is a brain-permeable activator of SIRT1, used for the research of type 2 diabetes mellitus and Huntington's disease. |
In Vivo: | SRT2104 (100 mg/kg, p.o.) improves whole-body physiology and extends lifespan in mice fed a standard diet. SRT2104 increases mitochondrial content and suppresses the inflammatory response in SD-fed mice. SRT2104 also changes the gene expression profile differently in liver and muscle. Short-term SRT2104 preserves muscle and bone mass[1]. 0.5% SRT2104 diet penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival in a mouse model of Huntington's disease[2]. |
In Vitro: | SRT 2104 (3 μM) reduces p65/RelA acetylation levels in C2C12 cells[1]. |